Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer

April 6th 2016

Colin Weekes, MD, PhD, gives insight into the current state and future directions for neoadjuvant therapy for pancreatic cancer.

Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC

April 5th 2016

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Earlier Nab-Paclitaxel/Gemcitabine Explored in Pancreatic Cancer

April 4th 2016

A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.

NCCN Guideline Expands Locoregional Treatment Candidates in HCC

April 1st 2016

Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

March 31st 2016

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

Combination Therapies Explored in Pancreatic Cancer Subgroups

March 25th 2016

To address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.

Second-Line Liposomal Irinotecan Added to NCCN Guideline for Pancreatic Cancer

March 24th 2016

The combination of liposomal irinotecan (irinotecan liposome injection; Onivyde), fluorouracil, and leucovorin has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

March 14th 2016

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials

March 10th 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

Adjuvant Care at High-Volume Centers Shows Improved Survival in Pancreatic Cancer

March 6th 2016

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

FDA Approves Everolimus for GI, Lung NETs

February 26th 2016

The FDA has approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.

Potential Biomarkers in Metastatic Colorectal Cancer

February 26th 2016

PI3K-Mutant Metastatic Colorectal Cancer

February 26th 2016

Microsatellite Instability Status in Colorectal Cancer

February 26th 2016

BRAF Testing in Colorectal Cancer

February 26th 2016

Pathways of Resistance in Metastatic Colorectal Cancer

February 26th 2016

Upfront EGFR Therapy in Metastatic Colorectal Cancer

February 26th 2016

EGFR Therapy as Upfront Colorectal Cancer Treatment

February 26th 2016